Selective protection of toxicity of 2′,3′-dideoxypyrimidine nucleoside analogs by β-D-uridine in human granulocyte-macrophage progenitor cells

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 261-267

  Faraj, Abdesslem ^a   Schinazi, Raymond F ^b,c   Xie, Meng Yu ^a   Gosselin, Gilles ^d   Perigaud, Christian ^d   Imbach, Jean Louis ^d   Sommadossi, Jean Pierre ^a,e  

^a University of Alabama at Birmingham   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

AMT; AZT; CFU GM; FLT; D uridine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

2',3' DIDEOXYPYRIMIDINE NUCLEOSIDE DERIVATIVE; 3' AMINO 3' DEOXYTHYMIDINE; 3' FLUOROTHYMIDINE; ALPHA URIDINE; BETA URIDINE; BETA URIDINE 5' BIS(S ACETYL 2 THIOETHYL)PHOSPHOTRIESTER; BETA URIDINE 5' MONOPHOSPHATE; DRUG METABOLITE; PRODRUG; THYMIDINE; UNCLASSIFIED DRUG; URACIL; ZIDOVUDINE;

ARTICLE; BONE MARROW SUPPRESSION; CELL CULTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NORMAL HUMAN; PRIORITY JOURNAL; PROTECTION; STEM CELL; STEREOISOMERISM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BONE MARROW CELLS; CELLS, CULTURED; DIDEOXYNUCLEOSIDES; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HIV; HUMANS; MACROPHAGES; MOLECULAR STRUCTURE; URIDINE; ZIDOVUDINE;

EID: 0029915098     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00905-1     Document Type: Article

References (30)

1. Collier, A.C., Bozzette, S., Coombs, R.W., Causey, D.M., Schoenfeld, D.A., Spector, S.A., Pettinelli, C.B., Davis, G., Richman, D.D., Leedom, J.M., Kid, P. and Corey, L. (1990) A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Eng. J. Med. 323, 1015-1021.
2. Cox, S. (1991) Studies on the reversal of azidothymidine toxicity in human lymohocytes by cytidine and uridine. Antiviral Chem. Chemother. 2, 23-28.
3. Cox, S. (1992) Metabolism of 3′-azido-3′-deoxythymidine and 3′-fluoro-3′-deoxythymidine in combination in human immunodeficiency virus infected lymphocytes. Antiviral Chem. Chemother. 3, 165-170.
4. Cretton, E.M., Xie, M.-Y., Bevan, R.J., Goudgaon, N.M., Schinazi, R.F. and Sommadossi, J.-P. (1991a) Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol. Pharmacol. 39, 258-266.
5. Cretton, E.M., Schinazi, R.F., McClure, H.M., Anderson, D.C. and Sommadossi, J.-P. (1991b) Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob. Agents Chemother. 35, 801-807.
6. Dainiak, N., Worthington, M., Riordan, M.A., Kreczko, S. and Goldman, L. (1988) 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br. J. Haematol. 69, 299-304.
7. Debart, F., Rayner, B., Degois, G. and Imbach, J.-L. (1992) Synthesis and base-pairing properties of the nuclease-resistanl α-anomeric dodecaribonucleotide α-[4(UCUUAACCCACA)]. Nucleic Acids Res. 20, 1193-1200.
8. Du, D.L., Volpe, D.A., Grieshaber, C.K. and Murphy, Jr., M.J. (1990) In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp. Hematol. 18, 832-836.
9. Faraj, A., Fowler, D.A., Bridges, E.G. and Sommadossi, J.-P. (1994) Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38, 924-930.
10. Fischl, M.A., Richman, D.D., Grieco, M.A., Gottlieb, M.S., Volberding, P.A., Laskin, O.L, Leedom, J.M., Groopman, J.E., Mildran, D., Shooley, R.T., Jackson, G.G., Durack, D.T., King, D. and the AZT Collaborative Working Group. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Eng. J. Med. 317, 185-191.
11. Fiscehl, M.A., Parker, C.B., Pettinelli, C., Wulfsohn, M., Hirsch, M.S., Collier, A.C., Antoniskis, D., Ho, M., Richman, D.D., Fuchs, E., Merigan, T.C., Reichman, R.C., Gold, J., Steigbigel, N., Leoung, G.S., Rasheed, S., Tsiatis, A, and the AIDS Clinical Trials Group. (1990) A randomized controlled trial to reduce daily dose of zidovudine in patients with AIDS and AIDS-related complex. N. Eng. J. Med. 323, 1009-1014.
12. Flexner, C., van der Horst, C., Jacobson, M.A., Powderly, W., Duncanson, F., Ganes, D., Barditch-Crovo, P.A., Petty, B.G., Baron, P.A., Armstrong, D., Bricmont, P., Kuye, O., Yacobi, A., DesJardins, R. and Polsky, B. (1994) Relationship between plasma concentration of 3′-deoxy-3′-fluorothymidine (Alovudine) and antiretroviral activity in two concentration-controlled trials. J. Infect. Dis. 170, 1394-1403.
13. Gallicchio, V.S., Hughes, N.K., Hulette, B.C. and Noblitt, L. (1991) Effect of interleukin-1, GM-CSF, erythropoietin, and lithium on the toxicity associated with 3′-azido-3′-de-oxythymidine (AZT) in vitro on hematopoietic progenitors (CFU-GM, CFU-MEG, and BFU-E) using murine retrovirus-infected hematopoietic cells. J. Leuko. Biol. 50, 580-586.
14. Ganser, A., Greher, J., Volkers, B., Staszewki, S. and Hoelzer, D. (1989) Inhibitory effect of azidothymidine, 2′,3′-dideoxyadenosine, and 2′,3′-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS. Exp. Hematol. 17, 321-325.
15. Gil, P.S., Rarick, M., Byrnes, R.K., Causey, D., Loureiro, C. and Levine, A.M. (1987) Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 107, 502-505.
16. Harmenberg, J., Akesson Johansson, A., Vrang, L. and Cox, S. (1990) Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3′-azido-3′-deoxythymidine and 3′-fluoro-3′-deoxythymidine. AIDS Res. Hum. Retroviruses 6, 1197-1202.
17. Holy, A. (1973) Nucleic acid components and their analogs. CLV. Mechanism of anomalous opening of O-2,2′-anhydro bond in uracil anhydronucleosides. Collect. Czech. Chem. Commun. 38, 423-427.
18. Johnson, M., Caiazzo, T., Molina, J.M., Donahue, R. and Groopman, J. (1988) Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br. J. Haematol. 70, 137-141.
19. Lefebvre, I., Perigaud, C., Pompon, A., Aubertin, A.-M., Girardet, J.-L., Kirn, A., Gosselin, G. and Imbach, J.-L. (1995) Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38, 3941-3950.
20. Perigaud, C., Gosselin, G., Lefevre, I., Girardet, J.L., Benzaria, S., Barber, I. and Imbach, J.L. (1993) Rational design for cytosolic delivery of nucleoside monophosphates: 'SATE' and 'DET' as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3, 2521-2526.
21. Perigaud, C., Aubertin, A.-M., Benzaria, S., Pelicano, H., Girardet, J.E., Maury, G., Gosselin, G., Kirn, A. and Imbach, J.E. (1994) Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 48, 11-14.
22. Richman, D.D., Fischl, M.A., Grieco, M.A., Gottlieb, M.S., Volberding, P.A., Easkin, O.L., Leedom, J.M., Groopman, J.E., Mildran, D., Hirsh, M.S., Jackson, G.G., Durack, D.T., Nusinoff-Lehrman, S. and the AZT Collaborative Working Group. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Eng. J. Med. 317, 192-197.
23. Sommadossi, J.-P. (1993) Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16, S7-S15.
24. Sommadossi, J.-P. and Carlisle, R. (1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoeitic cells in vitro. Antimicrob. Agents Chemother. 31, 452-454.
25. Sommadossi, J.-P., Carlisle, R., Schinazi, R.F. and Zhou, Z. (1988) Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob. Agents Chemother. 32, 997-1001.
26. Sommadossi, J.-P., Cretton, E., Kidd, L., McClure, H., Anderson, D. and el Kouni, M. (1995) Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy. Cancer Chemother. Pharmacol. 37, 14-22.
27. Staag, M.P., Cretton, E.M., Kidd, L., Diasio, R.B. and Sommadossi, J.-P. (1992) Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 51, 668-676.
28. Szebeni, J.S., Patel, S., Hung, K., Vahl, L.M and Weinstein, J.N. (1991) Effects of thymidine and uridine on the phosphorylation of 3′-azido-3′-deoxythymidine (zidovudine) in human mononuclear cells. Antimicrob. Agents Chemother. 35, 198-200.
29. Wu, A.F. and Chargaff, E. (1969) L-Uridine: synthesis and behaviour as enzyme substrate. Proc. Natl. Acad. Sci. U.S.A. 63, 122-126.
30. Yarchoan, R., Weinhold, K.J., Lyerly, H.K., Gelmann, E., Blum, R.M., Shearer, G.M., Mitsuya, H., Collins, J.M., Myers, C.E., Klecker, R.W., Markham, P.D., Durack, D.T., Nusinoff-Lehrman, S., Barry, D.W., Fischl, M.A., Gallo, R.C., Bolognesi, D.B. and Broder, S. (1986) Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication to patients with AIDS and AIDS-related complex. Lancet i, 575-580.